^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Ependymoma

    Related cancers:
    Apply
    Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors (SEL-TH-1601) (NCT03095248)
    Phase 2
    Children's Hospital Medical Center, Cincinnati
    Suspended
    Last update posted :
    06/12/2024
    Initiation :
    05/08/2017
    Primary completion :
    06/01/2024
    Completion :
    06/01/2025
    NF2
    |
    NF2 mutation
    |
    Koselugo (selumetinib)
    Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma (NCT02359565)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    05/22/2015
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    PD-L1 • TMB
    |
    TMB-H
    |
    Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)
    Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors (NCT01445288)
    Phase N/A
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    06/10/2024
    Initiation :
    12/05/2006
    VEGFA • TNFA
    Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (NCT03155620)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/06/2024
    Initiation :
    07/31/2017
    Primary completion :
    09/30/2027
    Completion :
    09/30/2027
    BRAF
    |
    Lynparza (olaparib) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Vitrakvi (larotrectinib) • Koselugo (selumetinib) • Balversa (erdafitinib) • Retevmo (selpercatinib) • Ensacove (ensartinib) • Zarnestra (tipifarnib) • Tazverik (tazemetostat) • ulixertinib (BVD-523) • samotolisib (LY3023414)
    Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers (NCT03173950)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/05/2024
    Initiation :
    07/13/2017
    Primary completion :
    04/21/2026
    Completion :
    04/21/2027
    BCOR • FOXR2
    |
    Opdivo (nivolumab)
    PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications (NCT06161519)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/05/2024
    Initiation :
    01/31/2024
    Primary completion :
    11/14/2028
    Completion :
    11/14/2033
    MYCN
    |
    MYCN amplification
    |
    PLX038
    Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors (PNOC028) (NCT05887882)
    Phase 1
    Sabine Mueller, MD, PhD
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    05/31/2024
    Primary completion :
    12/31/2027
    Completion :
    12/31/2027
    TGFB1 • TGFBI
    SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors (NCT03434262)
    Phase 1
    St. Jude Children's Research Hospital
    Completed
    Last update posted :
    05/31/2024
    Initiation :
    03/05/2018
    Primary completion :
    09/30/2022
    Completion :
    05/24/2024
    PTCH1
    |
    PTCH1 mutation
    |
    Mekinist (trametinib) • gemcitabine • Kisqali (ribociclib) • Odomzo (sonidegib) • Neupogen (filgrastim)
    Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) (NCT03526250)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/21/2024
    Initiation :
    08/13/2018
    Primary completion :
    03/31/2023
    Completion :
    09/22/2024
    RB1
    |
    Ibrance (palbociclib)
    Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) (NCT03213678)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/21/2024
    Initiation :
    11/28/2017
    Primary completion :
    09/30/2023
    Completion :
    10/01/2024
    PTEN • TSC2 • TSC1
    |
    PTEN expression • TSC1 mutation • TSC2 mutation
    |
    samotolisib (LY3023414)
    Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) (NCT03213704)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/21/2024
    Initiation :
    08/23/2017
    Primary completion :
    09/30/2024
    Completion :
    09/30/2024
    NTRK
    |
    NTRK fusion
    |
    Vitrakvi (larotrectinib)
    Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) (NCT03220035)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    11/08/2017
    Primary completion :
    06/30/2022
    Completion :
    09/22/2024
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    Zelboraf (vemurafenib)
    Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma (NCT02101905)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    04/29/2024
    Initiation :
    03/13/2014
    Primary completion :
    10/19/2021
    Completion :
    10/19/2024
    EGFR
    |
    EGFR amplification
    |
    lapatinib
    Phase I Study of APX005M in Pediatric CNS Tumors (NCT03389802)
    Phase 1
    Pediatric Brain Tumor Consortium
    Active, not recruiting
    Last update posted :
    04/08/2024
    Initiation :
    03/01/2018
    Primary completion :
    09/30/2023
    Completion :
    09/30/2024
    TMB • CD4
    |
    sotigalimab (PYX-107)
    Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children (NCT03043391)
    Phase 1
    Istari Oncology, Inc.
    Completed
    Last update posted :
    04/08/2024
    Initiation :
    11/07/2017
    Primary completion :
    03/23/2022
    Completion :
    03/23/2022
    NF1
    |
    NF1 mutation
    |
    lerapolturev (PVS-RIPO)
    Molecular-Guided Therapy for Childhood Cancer (NCT02162732)
    Phase N/A
    Giselle Sholler
    Completed
    Last update posted :
    04/05/2024
    Initiation :
    07/08/2014
    Primary completion :
    01/18/2024
    Completion :
    01/18/2024
    MYCN
    |
    MYCN amplification
    HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma (NCT04903080)
    Phase 1
    Pediatric Brain Tumor Consortium
    Recruiting
    Last update posted :
    04/05/2024
    Initiation :
    07/27/2022
    Primary completion :
    07/20/2028
    Completion :
    07/20/2043
    HER-2
    |
    HER-2 positive
    |
    cyclophosphamide
    Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases (NCT03796273)
    Phase 1
    Wake Forest University Health Sciences
    Recruiting
    Last update posted :
    04/03/2024
    Initiation :
    03/13/2019
    Primary completion :
    07/01/2024
    Completion :
    09/01/2024
    KDR • CD24 • POU5F1 • VEGFC
    131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (NCT04743661)
    Phase 2
    Pediatric Brain Tumor Consortium
    Active, not recruiting
    Last update posted :
    03/29/2024
    Initiation :
    04/04/2022
    Primary completion :
    10/30/2029
    Completion :
    10/30/2030
    CD276
    |
    Avastin (bevacizumab) • temozolomide • irinotecan • Omblastys (131I-omburtamab) • dexamethasone injection • ondansetron intravenous
    Study of the Effect of GM-CSF on Macrophages in Ependymoma (NCT04408092)
    Phase 1
    University of Colorado, Denver
    Completed
    Last update posted :
    03/15/2024
    Initiation :
    06/25/2013
    Primary completion :
    09/21/2021
    Completion :
    07/21/2023
    AIF1
    Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors (NCT05835687)
    Phase 1
    St. Jude Children's Research Hospital
    Recruiting
    Last update posted :
    03/13/2024
    Initiation :
    04/27/2023
    Primary completion :
    03/01/2028
    Completion :
    03/01/2028
    CD276
    |
    B7-H3 CAR-T
    Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) (NCT04374305)
    Phase 2
    Scott R. Plotkin, MD, PhD
    Recruiting
    Last update posted :
    03/13/2024
    Initiation :
    06/20/2020
    Primary completion :
    12/01/2029
    Completion :
    12/01/2030
    NF2
    |
    Nerlynx (neratinib) • Alunbrig (brigatinib)
    Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors (NCT02100891)
    Phase 2
    Monica Thakar
    Completed
    Last update posted :
    03/12/2024
    Initiation :
    03/20/2013
    Primary completion :
    06/08/2020
    Completion :
    07/15/2020
    HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
    INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies (INFORM2 NivEnt) (NCT03838042)
    Phase 1/2
    University Hospital Heidelberg
    Recruiting
    Last update posted :
    02/07/2024
    Initiation :
    05/26/2020
    Primary completion :
    06/30/2026
    Completion :
    06/30/2027
    PD-L1 • TMB • MYC
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Jingzhuda (entinostat)
    Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors (NCT01661400)
    Phase 1
    Washington University School of Medicine
    Completed
    Last update posted :
    01/31/2024
    Initiation :
    10/26/2012
    Primary completion :
    12/27/2023
    Completion :
    12/27/2023
    CD34
    |
    cyclophosphamide • thalidomide • cyclophosphamide intravenous
    Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma (NCT02774421)
    Phase 1
    University of Colorado, Denver
    Recruiting
    Last update posted :
    12/25/2023
    Initiation :
    12/01/2016
    Primary completion :
    11/01/2025
    Completion :
    03/01/2026
    CSF2
    |
    Herceptin (trastuzumab)
    HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors (NCT03500991)
    Phase 1
    Seattle Children's Hospital
    Active, not recruiting
    Last update posted :
    12/20/2023
    Initiation :
    07/26/2018
    Primary completion :
    07/26/2024
    Completion :
    07/26/2039
    HER-2
    |
    HER-2 positive
    |
    HER2-Specific CAR T
    Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors (NCT04185038)
    Phase 1
    Seattle Children's Hospital
    Recruiting
    Last update posted :
    12/20/2023
    Initiation :
    12/11/2019
    Primary completion :
    05/01/2026
    Completion :
    05/01/2041
    CD276
    |
    CD276 expression
    |
    SCRI-CARB7H3(s)
    EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors (NCT03638167)
    Phase 1
    Seattle Children's Hospital
    Active, not recruiting
    Last update posted :
    10/27/2023
    Initiation :
    03/19/2019
    Primary completion :
    03/01/2025
    Completion :
    03/01/2040
    EGFR
    |
    EGFR expression • EGFR positive
    |
    EGFR806-specific CAR T-cell therapy
    Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer (NCT04521946)
    Phase 1
    M.D. Anderson Cancer Center
    Withdrawn
    Last update posted :
    10/04/2023
    Initiation :
    01/14/2021
    Primary completion :
    12/20/2022
    Completion :
    12/20/2022
    HLA-DRB1 • HLA-B • HLA-C • KIR2DS2
    |
    etoposide IV • melphalan • fludarabine IV • thiotepa
    A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 (NCT03152318)
    Phase 1
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    08/08/2023
    Initiation :
    07/18/2017
    Primary completion :
    12/01/2024
    Completion :
    12/01/2025
    IDH1
    |
    IDH1 mutation • IDH1 R132H • IDH wild-type • IDH1 R132
    |
    cyclophosphamide • CAN-3110
    Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors (NCT03220646)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    07/07/2023
    Initiation :
    07/13/2017
    Primary completion :
    07/01/2024
    Completion :
    07/01/2024
    EGFR • FGFR
    |
    IDH wild-type
    |
    cisplatin • Verzenio (abemaciclib)
    Temozolomide and Radiation Therapy in Treating Patients With Gliomas (NCT00114140)
    Phase 2
    Radiation Therapy Oncology Group
    Completed
    Last update posted :
    06/14/2022
    Initiation :
    01/01/2005
    Primary completion :
    02/01/2013
    Completion :
    05/20/2022
    MGMT
    |
    temozolomide
    Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors (NCT03387020)
    Phase 1
    Pediatric Brain Tumor Consortium
    Completed
    Last update posted :
    08/27/2021
    Initiation :
    01/13/2018
    Primary completion :
    04/01/2020
    Completion :
    04/01/2020
    RB1
    |
    everolimus • Kisqali (ribociclib)
    Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas (NCT01125046)
    Phase 2
    Northwestern University
    Completed
    Last update posted :
    01/22/2021
    Initiation :
    06/17/2010
    Primary completion :
    03/10/2014
    Completion :
    12/31/2018
    HER-2
    |
    HER-2 expression • VEGFA expression
    |
    Avastin (bevacizumab)
    Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors (NCT01331135)
    Phase 1
    Emory University
    Completed
    Last update posted :
    05/29/2020
    Initiation :
    04/01/2011
    Primary completion :
    08/09/2017
    Completion :
    08/09/2017
    AFP
    |
    sirolimus
    A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors (NCT00994071)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    12/09/2019
    Initiation :
    09/22/2009
    Completion :
    03/19/2013
    AFP
    |
    temozolomide • veliparib (ABT-888)
    Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer (NCT01325207)
    Phase 1/2
    Northwestern University
    Completed
    Last update posted :
    09/26/2019
    Initiation :
    08/01/2011
    Primary completion :
    06/20/2016
    Completion :
    01/20/2019
    HER-2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab)